Showing of 9 results
UH Seidman Cancer Center Opens New Trial with PVSRIPO, a Viral-based Immunotherapy in Combination with Pembrolizumab for Patients with Recurrent GBM
The two therapies may be able to generate a potent and specific anti-tumor response in rGBM patients, given their different but complimentary mechanisms of action - Innovations in Cancer | Fall 2020
UH Research & Education Update | July 2020
New $2.7 million grant from the National Cancer Institute will help validate promising approach - Innovations in Cancer | Summer 2019
5-ALA helps surgeons visualize boundaries of invading tumors for more complete removal - Innovations in Neurology & Neurosurgery - Winter 2019
Distinguishes tumor from healthy tissue to improve tumor removal The imaging agent 5-Aminolevulinic Acid (5-ALA), which helps neurosurgeons see the edges of a tumor more clearly to improve removal, was used in brain cancer surgery at University...
UH Neurological Institute - Summer 2018 University Hospital’s Neurological Institute works closely with UH Seidman Cancer Center to offer cutting-edge treatments for primary and metastatic cancers of the brain and spine and for non-metastatic...
Magnetic resonance fingerprinting technology developed in Cleveland shows promise in adult brain tumors - Innovations in Cancer | Spring 2017